Cellectar Biosciences
CLRB
20 hedge funds and large institutions have $1.04M invested in Cellectar Biosciences in 2025 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 1 reducing their positions, and 5 closing their positions.
600% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 1
1.1% less ownership
Funds ownership: 9.28% → 8.18% (-1.1%)
5% less funds holding
Funds holding: 21 → 20 (-1)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
37% less capital invested
Capital invested by funds: $1.65M → $1.04M (-$608K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DS
DRW Securities
Chicago,
Illinois
|
+$88.9K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$88.4K |
| 3 |
SFA
Sequoia Financial Advisors
Akron,
Ohio
|
+$53.8K |
| 4 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
+$51.3K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$45.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$139K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$104K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$73K |
| 4 |
Group One Trading
Chicago,
Illinois
|
-$129 |
| 5 |
Citigroup
New York
|
-$106 |
CLRB Hedge Fund Activity: Q4 2025 in Review
20 of the 8,281 institutional investors tracked by Wall St. Rank reported a position in Cellectar Biosciences (CLRB) for Q4 2025, worth a combined $1.04M — down 37% from $1.65M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of CLRB and 4 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 7 added.
The largest buyer was DRW Securities, adding an estimated $88.9K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $139K sold.
- 20 institutional investors held Cellectar Biosciences (CLRB) as of Q4 2025, down from 21 in Q3 2025.
- Funds reported $1.04M of Cellectar Biosciences stock for Q4 2025, down 37% quarter-over-quarter.
- 4 funds opened new Cellectar Biosciences positions in Q4 2025 and 5 closed out, a net change of -1 holder.
- The largest Cellectar Biosciences buyer in Q4 2025 was DRW Securities, an estimated $88.9K added.
- The largest Cellectar Biosciences seller in Q4 2025 was Renaissance Technologies, an estimated $139K sold.
Based on aggregated 13F filings for Q4 2025.